Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Gomez-Arteaga A, Orfali N, Guarneri D, Cushing MM, Gergis U, Hsu JM, et al. Cord blood transplants supported by unrelated donor CD34 progenitor cells. Bone Marrow Transplant. 2020;55(12):2298-2307.

Li S, Kendall J, Park S, Wang Z, Alexander J, Moffitt A, et al. Copolymerization of single-cell nucleic acids into balls of acrylamide gel. Genome Res. 2020;30(1):49-61.

Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, et al. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol. 2020;95(12):1553-1561.

Zanettini C, Omar M, Dinalankara W, Imada EL, Colantuoni E, Parmigiani G, et al. Influenza Vaccination and COVID19 Mortality in the USA. medRxiv. 2020.

Manur R, Sung PJ, Loren AW, Ritchie EK, Frank D, Bagg A, et al. Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/-rearranged myeloid/lymphoid neoplasm with mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib. Leuk Lymphoma. 2020;61(2):450-454.

Marzio A, Pagano M. Loss of the deubiquitinase OTULIN promotes hepatocellular carcinoma (HCC) in an mTOR-dependent manner. Cell Death Differ. 2020;27(5):1455-1456.

Yang HS, Racine-Brzostek SE, Karbaschi M, Yee J, Dillard A, Steel PA, et al. Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. medRxiv. 2020.

Bagheri S, Pantrangi M, Sodhi SK, Bagheri S, Oellers P, Scholl HP. A NOVEL LARGE HOMOZYGOUS DELETION IN THE CELLULAR RETINALDEHYDE-BINDING PROTEIN GENE (RLBP1) IN A PATIENT WITH RETINITIS PUNCTATA ALBESCENS. Retin Cases Brief Rep. 2020;14(1):85-89.

Hadi K, Yao X, Behr JM, Deshpande A, Xanthopoulakis C, Tian H, et al. Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. Cell. 2020;183(1):197-210.e32.

Burkhart DL, Morel KL, Wadosky KM, Labbé DP, Galbo PM, Dalimov Z, et al. Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer Prev Res (Phila). 2020;13(12):979-988.